Description: Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Home Page: fractyl.com
3 Van de Graaff Drive
Burlington,
MA
01803
United States
Phone:
781 902 8800
Officers
| Name | Title |
|---|---|
| Dr. Harith Rajagopalan M.D., Ph.D. | Co-Founder, CEO & Director |
| Mr. Jay D. Caplan BSEE, MBA | Co-Founder, Chief Product Officer & President |
| Dr. Timothy J. Kieffer Ph.D. | Chief Scientific Officer |
| Ms. Lisa A. Davidson MBA | CFO & Treasurer |
| Ms. Sarah S. Toomey Esq. | General Counsel & Corporate Secretary |
| Mr. Adrian Kimber | Chief Commercial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.1076 |
| Price-to-Sales TTM: | 1130.574 |
| IPO Date: | 2024-02-02 |
| Fiscal Year End: | September |
| Full Time Employees: | 122 |